Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
The Trump administration allowed a waiver that encouraged more Russian crude sales to lapse, even as the Iran war stokes...
Cathie Wood, chief of Ark Investment Management, is known for actively trading her holdings, sometimes selling stocks during sharp market...
US officials have discussed creating a $1.7 billion federal fund to pay victims of so-called government weaponization to resolve President Donald Trump’s...
The $1 trillion club used to be fairly exclusive. Now, it's becoming a lot more crowded. As of the time...
The biggest IPO ever is just a few weeks away as reports say SpaceX has accelerated its timeline for coming...
Throughout both of his terms, President Donald Trump has stood firm on immigration control, perhaps even more so this time...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
(1)-1024x683.jpg "State Department Says Remigration, Not Replacement Migration")
